secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bicara Therapeutics Inc. (BCAX)
CIK:        0002023658
Form:       8-K
Filed at:   2026-08-11T11:36:11+00:00
Accession:  0001628280-26-055500
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicara names Ryan Cohlhepp CEO effective Jan 2027; Q2 net loss widens to $55.4M
-------------------------------------------------------------------------------

- Net loss $55.4M in Q2 2026 vs $27.4M in Q2 2025; R&D expense $45.8M (up from $24.8M).
- Cash, equivalents, marketable securities $497.3M at June 30, 2026; funded into 1H 2029.
- Ryan Cohlhepp (President/COO) to become CEO Jan 1, 2027; Claire Mazumdar moves to Vice Chair.
- Tanya Green promoted to COO, Jenn Larson appointed CFO effective Aug 12, 2026; other C-suite changes.
- FORTIFI-HN01 pivotal trial substantially enrolled by year-end; interim topline mid-2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023658/000162828026055500/0001628280-26-055500-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023658/000162828026055500/bcax-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-055500

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer